Retatrutide
retatrutide
triple incretin agonist
Retatrutide is a next-generation obesity drug candidate built around GLP-1, GIP, and glucagon receptor agonism.
fat-loss|metabolism|obesity-research
It combines incretin signaling with glucagon-pathway activation, aiming to enhance appetite suppression, metabolic regulation, and energy expenditure.
Late Clinical | Investigational
advanced-metabolic-stack
fat-loss|metabolism|obesity-research
retatrutide-vs-tirzepatide|semaglutide-vs-tirzepatide
/images/retatrutide.jpg
published